Statins Prevent Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Single-center Retrospective Study with a Median Follow-up of 51.20 Months

References

• Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15(1):3866.18304396
   PubMed Web of Science ®Google Scholar
• Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28(3):555–565. doi:10.1016/S0094-0143(05)70163-411590814
   PubMed Web of Science ®Google Scholar
• Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64(1):102–146.22106090
   PubMed Web of Science ®Google Scholar
• Carlberg M, Dricu A, Blegen H, et al. Mevalonic acid is limiting for n-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem. 1996;271(29):17453–17462. doi:10.1074/jbc.271.29.174538663239
   PubMed Web of Science ®Google Scholar
• Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16(4):508. doi:10.1038/sj.leu.240247611960327
   PubMed Web of Science ®Google Scholar
• Dulak J, Józkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005;5(8):579–594. doi:10.2174/15680090577493282416375664
   PubMed Web of Science ®Google Scholar
• Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest. 2007;131(5):1282–1288. doi:10.1378/chest.06-093117494779
   PubMed Web of Science ®Google Scholar
• Poynter JN, Gruber SB, Higgins PDR, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184–2192. doi:10.1056/NEJMoa04379215917383
   PubMed Web of Science ®Google Scholar
• Kochhar R, Khurana V, Bejjanki H, Caldito G, Fort C. Statins to reduce breast cancer risk: a case control study in US female veterans. J Clin Oncol. 2005;23(16_suppl):514. doi:10.1200/jco.2005.23.16_suppl.514
   Web of Science ®Google Scholar
• Demierre M-F, Nathanson L. Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol. 2003;21(1):158–165. doi:10.1200/JCO.2003.07.17312506185
   PubMed Web of Science ®Google Scholar
• Parada B, Reis F, Pinto Â, et al. Chemopreventive efficacy of atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. Int J Mol Sci. 2012;13(7):8482–8499. doi:10.3390/ijms1307848222942715
   PubMed Web of Science ®Google Scholar
• Kumar A, Riviere P, Luterstein E, et al. Associations among statins, preventive care, and prostate cancer mortality. Prostate Cancer Prostatic Dis. 2020;1–11.
   Web of Science ®Google Scholar
• Tan P, Wei S, Yang L, et al. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis. Sci Rep. 2016;6(1):29106. doi:10.1038/srep2910627384548
   PubMed Web of Science ®Google Scholar
• Ericsson J, Edwards PA. Signaling Molecules Derived from the Cholesterol Biosynthetic Pathway. In: Bittman R, editor. Cholesterol. Subcellular Biochemistry. Boston, MA: Springer;  1997:1–21.
   Google Scholar
• Benitah SA, Espina C, Valerón PF, Lacal JC. Rho GTPases in human carcinogenesis: a tale of excess. Rev Oncol. 2003;5(2):70–78.
   Google Scholar
• Dillard PR, Lin M-F, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol. 2008;295(1–2):115–120. doi:10.1016/j.mce.2008.08.01318782595
   PubMed Web of Science ®Google Scholar
• Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977. doi:10.1038/nrd190116341063
   PubMed Web of Science ®Google Scholar
• Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol. 2007;99(5):732–738. doi:10.1016/j.amjcard.2006.09.12517317382
   PubMed Web of Science ®Google Scholar
• Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol. 2005;162(4):318–325. doi:10.1093/aje/kwi20316014776
   PubMed Web of Science ®Google Scholar
• Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar H-J. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388–2394. doi:10.1200/JCO.2004.02.02715197200
   PubMed Web of Science ®Google Scholar
• Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98(24):1819–1825. doi:10.1093/jnci/djj49917179483
   PubMedGoogle Scholar
• Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Prev Biomark. 2007;16(11):2213–2217. doi:10.1158/1055-9965.EPI-07-0448
   Web of Science ®Google Scholar
• Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California men’s health study cohort. Cancer Epidemiol Prev Biomark. 2007;16(11):2218–2225. doi:10.1158/1055-9965.EPI-07-0197
   Web of Science ®Google Scholar
• Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Prev Biomark. 2007;16(11):2226–2232. doi:10.1158/1055-9965.EPI-07-0599
   Web of Science ®Google Scholar
• Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst. 2008;100(21):1511–1518. doi:10.1093/jnci/djn36218957682
   PubMedGoogle Scholar
• Cyrus-David Mfon S, Armin W, Timothy T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol. 2005;173(6):1923–1925. doi:10.1097/01.ju.0000158044.94188.8815879782
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al; EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–479. doi:10.1016/j.eururo.2013.11.00224321502
   PubMed Web of Science ®Google Scholar
• Ku JH, Jeong CW, Park YH, Cho MC, Kwak C, Kim HH. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis. 2011;14(1):63. doi:10.1038/pcan.2010.3920938462
   PubMed Web of Science ®Google Scholar
• Krane LS, Kaul SA, Stricker HJ, Peabody JO, Menon M, Agarwal PK. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol. 2010;183(1):118–124. doi:10.1016/j.juro.2009.08.15119913252
   PubMed Web of Science ®Google Scholar
• Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol. 2011;185(4):1268–1273. doi:10.1016/j.juro.2010.11.08921334020
   PubMed Web of Science ®Google Scholar
• Rieken M, Kluth LA, Xylinas E, et al. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis. 2013;16(4):367–371. doi:10.1038/pcan.2013.3123999669
   PubMed Web of Science ®Google Scholar
• Mass AY, Agalliu I, Laze J, Lepor H. Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. J Urol. 2012;188(3):786–791. doi:10.1016/j.juro.2012.05.01122818136
   PubMed Web of Science ®Google Scholar
• Hamilton RJ, Banez LL, Aronson WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2010;116(14):3389–3398. doi:10.1002/cncr.2530820586112
   PubMed Web of Science ®Google Scholar
• Song C, Park S, Park J, et al. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer: impact of statin use on prostate cancer recurrence. Prostate. 2015;75(2):211–217. doi:10.1002/pros.2290725327522
   PubMed Web of Science ®Google Scholar
• Ritch CR, Hruby G, Badani KK, Benson MC, McKiernan JM. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int. 2011;108(8b):E211–E216. doi:10.1111/j.1464-410X.2011.10159.x21453350
   PubMed Web of Science ®Google Scholar